Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs) 2024-07-30 09:00
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis 2024-07-30 06:00
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia 2024-07-29 23:18
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin 2024-07-29 20:00
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA 2024-07-29 17:26
111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow 2024-07-29 13:00
A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST 2024-07-29 11:20
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder 2024-07-28 21:48
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation 2024-07-26 23:21
MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships 2024-07-26 21:02
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders 2024-07-26 21:00
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer 2024-07-26 20:16
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update 2024-07-26 19:00
Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project 2024-07-26 18:00
Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View 2024-07-26 17:05
Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View 2024-07-26 17:05
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 2024-07-26 10:16
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development 2024-07-26 09:33
Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy 2024-07-25 20:00
IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE) 2024-07-25 17:46
1 21 22 23 24 25 412